HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($3.62) per share for the year, up from their prior forecast of ($3.87). HC Wainwright has a “Buy” rating and a $158.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2026 earnings at ($1.06) EPS, Q1 2027 earnings at ($1.12) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.41) EPS, FY2029 earnings at ($5.42) EPS and FY2030 earnings at $2.35 EPS.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million.

A number of other analysts have also weighed in on DNTH. JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target for the company. Citigroup initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Roth Capital initiated coverage on shares of Dianthus Therapeutics in a report on Tuesday, October 27th. They set a “buy” rating and a $113.00 price target on the stock. Finally, Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $128.77.

View Our Latest Research Report on Dianthus Therapeutics

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $89.30 on Tuesday. Dianthus Therapeutics has a 12-month low of $34.29 and a 12-month high of $117.88. The firm has a market capitalization of $5.03 billion, a P/E ratio of -22.38 and a beta of 1.47. The business has a 50 day simple moving average of $89.05 and a 200 day simple moving average of $86.15.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $194,960,000. First Horizon Corp bought a new position in shares of Dianthus Therapeutics in the first quarter worth about $32,000. EFG International AG acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $49,000. GAMMA Investing LLC grew its position in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after acquiring an additional 254 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Dianthus Therapeutics by 23.6% during the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after purchasing an additional 129 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CAO Edward Carr sold 20,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the transaction, the chief accounting officer owned 20,000 shares of the company’s stock, valued at approximately $2,027,600. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Simrat Randhawa sold 23,124 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This represents a 85.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 45,902 shares of company stock valued at $4,814,779. 3.02% of the stock is currently owned by insiders.

Top Dianthus Therapeutics Stories

These are some of the DNTH stories that stood out recently:

  • Positive Sentiment: HC Wainwright raised its EPS estimates for 2026 through 2028 and several 2027 quarters, while maintaining a Buy rating and a $158 price target. The improved forecasts may support sentiment, although the company is still expected to report losses in those periods. MarketBeat coverage
  • Neutral Sentiment: A short-interest report listed 0 shares short as of November 10, despite describing short interest as having increased. The figures appear inconsistent, so they provide little clear signal about investor positioning.
  • Negative Sentiment: HC Wainwright cut its FY2029 EPS estimate from a loss of $0.13 to a loss of $5.42 and its FY2030 estimate from earnings of $10.75 to $2.35. Separately, an article said DNTH may look stretched as investors focus on pipeline progress, flagging valuation risk after the stock’s strong run. Dianthus Therapeutics stock may look stretched

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

Featured Stories

Earnings History and Estimates for Dianthus Therapeutics (NASDAQ:DNTH)

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.